STATEMENT: MAPS-Funded Phase 3 Research Reports Results from Long-Term Observational Follow-Up Study on MDMA-Assisted Therapy for PTSD


  • Interim results show improvements in PTSD symptom severity lasted at least six months after the last treatment session

MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), announced preliminary findings from the observational study Long-Term Safety and Persistence of Effectiveness of Manualized MDMA-Assisted Therapy for the Treatment of Posttraumatic Stress Disorder (MPLONG). According to MAPS PBC, these preliminary findings “show that participants in this study demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the Phase 3 study.” 

The first long-term observational follow-up analysis of six pooled phase 2 trials, published in Psychopharmacology in 2020, demonstrated that the treatment effects were sustained for at least one year following the treatment sessions.  

MDMA-assisted therapy is initially intensive — for both participants and practitioners — because it’s a process that seeks to treat root causes rather than just minimize symptoms. While patients and practitioners need to know the treatment effects could be long-lasting to invest their time, insurers need to understand the same to provide coverage. The results of this follow-up study suggest the durability of treatment results and the financial viability of MDMA-assisted therapy for PTSD.

Rick Doblin, Ph.D., Founder and President, MAPS

Keep Reading…


The safety and efficacy of psychedelic-assisted therapies are currently under investigation. No psychedelic-assisted therapy has been approved by the FDA or other regulatory authorities; no therapy works for everyone; and all therapies, even in clinical settings, carry risks.

Founded in 1986, MAPS is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. MAPS is sponsoring the most advanced psychedelic therapy research in the world through its wholly-owned subsidiaries MAPS PBC and MAPS EU. Since MAPS was founded, philanthropic donors and grantors have given more than $145 million for psychedelic and marijuana research and education. MAPS has earned both the Guidestar Platinum Seal of Transparency and a 4-Star Rating from Charity Navigator.